• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于淋巴瘤定位和分期的枸橼酸镓-67扫描。

Gallium-67-citrate scanning for the localization and staging of lymphomas.

作者信息

Adler S, Parthasarathy K L, Bakshi S P, Stutzman L

出版信息

J Nucl Med. 1975 Apr;16(4):255-60.

PMID:1089769
Abstract

One-hundred-eight 67Ga-citrate scans were evaluated in Hodgkin's and non-Hodgkin's lymphomas for staging, diagnosis of recurrence, and for determing the results of treatment. Accuracy as confirmed by comparing the scans with pathologic material or roentgenologic and clinical findings was found to be 83%. Known lymph node involvement was diagnosed correctly in 87% but accuracy was only 48% for extranodal areas. Bone lesions were diagnosed correctly in 83% compared with only 48% of lesions of the lungs and liver. Scans were 75% accurate in 28 patients scanned for initial staging. False negatives were present in 12%; recurrent tumor in an area of prior radiation therapy appeared to be the most common cause. There were 5% false positives. Gallium scanning is a useful adjunct to other methods of detecting lymphoma.

摘要

对108例霍奇金淋巴瘤和非霍奇金淋巴瘤患者进行了67镓柠檬酸盐扫描,以进行分期、诊断复发情况以及确定治疗结果。通过将扫描结果与病理材料或放射学及临床检查结果进行比较,发现其准确率为83%。已知的淋巴结受累情况诊断正确率为87%,但结外区域的诊断准确率仅为48%。骨病变的诊断正确率为83%,而肺部和肝脏病变的诊断正确率仅为48%。对28例进行初始分期扫描的患者,扫描准确率为75%。假阴性率为12%;既往放疗区域出现的复发性肿瘤似乎是最常见的原因。假阳性率为5%。镓扫描是检测淋巴瘤的其他方法的有用辅助手段。

相似文献

1
Gallium-67-citrate scanning for the localization and staging of lymphomas.用于淋巴瘤定位和分期的枸橼酸镓-67扫描。
J Nucl Med. 1975 Apr;16(4):255-60.
2
Gallium citrate Ga 67 scanning: clinical usefulness in lymphoma patients.枸橼酸镓Ga 67扫描:对淋巴瘤患者的临床应用价值
Arch Intern Med. 1976 Dec;136(12):1370-4.
3
Whole-body radiogallium scanning for staging of Hodgkin's disease and other lymphomas.用于霍奇金病及其他淋巴瘤分期的全身放射性镓扫描。
Natl Cancer Inst Monogr. 1973 May;36:277-85.
4
67Ga-citrate imaging in untreated malignant lymphoma: preliminary report of Cooperative Group.未治疗的恶性淋巴瘤的67Ga柠檬酸盐显像:协作组初步报告
J Nucl Med. 1974 Jun;15(6):404-7.
5
Scintigraphic evaluation of lymphoma: a comparative study of 67Ga-citrate and 111In-Bleomycin.淋巴瘤的闪烁显像评估:枸橼酸镓67与博来霉素铟111的对比研究
Radiology. 1977 Jun;123(3):687-94. doi: 10.1148/123.3.687.
6
[Ga-67 citrate scanning in the management of Hodgkin's disease (author's transl)].[枸橼酸镓-67扫描在霍奇金病治疗中的应用(作者译)]
Dtsch Med Wochenschr. 1975 Mar 21;100(12):593-6. doi: 10.1055/s-0028-1106263.
7
Radionuclide studies in Hodgkin's disease and lymphomas.霍奇金病和淋巴瘤的放射性核素研究
Semin Nucl Med. 1975 Jan;5(1):103-8. doi: 10.1016/s0001-2998(75)80008-0.
8
Gallium-67 citrate scanning in malignant lymphoma.枸橼酸镓-67扫描在恶性淋巴瘤中的应用
CRC Crit Rev Clin Radiol Nucl Med. 1975 Nov;7(1):65-96.
9
Role of 67gallium citrate scanning in the management of non-Hodgkin's lymphoma.枸橼酸镓扫描在非霍奇金淋巴瘤治疗中的作用。
Cancer. 1975 Nov;36(5):1690-741. doi: 10.1002/1097-0142(197511)36:5<1690::aid-cncr2820360524>3.0.co;2-y.
10
Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma.枸橼酸镓-67扫描在霍奇金病和非霍奇金淋巴瘤中的应用
Cancer. 1976 Jan;37(1):250-7. doi: 10.1002/1097-0142(197601)37:1<250::aid-cncr2820370134>3.0.co;2-n.

引用本文的文献

1
Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies.淋巴瘤:放射性标记抗体在临床及临床前成像中的现状
Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):517-532. doi: 10.1007/s00259-016-3560-9. Epub 2016 Nov 14.
2
Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.胃肠道淋巴瘤累及:(18)F-氟脱氧葡萄糖正电子发射断层扫描评估
World J Gastroenterol. 2005 Dec 14;11(46):7284-9. doi: 10.3748/wjg.v11.i46.7284.
3
Scintigraphic methods in the diagnosis of M. Hodgkin.
用于诊断霍奇金病的闪烁扫描法
Eur J Nucl Med. 1978;3(1):11-14. doi: 10.1007/BF00253471.
4
The urinary excretion of gallium-67 citrate in patients with neoplastic disease.
Eur J Nucl Med. 1979 Aug 1;4(4):277-82. doi: 10.1007/BF00304883.